Sepsis
Conditions
Interventions
Observation Group:Conventional treatment + adsorption therapy
Control Group:Conventional treatment
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.In accordance with the Sepsis-3.0 definition and diagnostic criteria jointly released by the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM) in 2016; 2.Sepsis diagnosis time =500 ng/L(pg/mL); 4.Age between 18 and 75 years old (inclusive), gender unrestricted; 5.The patient signs the informed consent form personally. If the patient is unconscious (e.g., due to coma, shock, or anesthesia) and unable to provide consent, their legal representative may sign the informed consent form on their behalf;
Exclusion criteria
Exclusion criteria: 1.Pregnant or breastfeeding women, or patients of childbearing potential unwilling/unable to use effective contraception; 2.Hypersensitivity to extracorporeal circulation materials, anticoagulants, or hemoperfusion agents, or a history of other severe allergies; 3.Patients with severe irreversible diseases, including terminal-stage malignancies; 4.Patients with immunodeficiency disorders, such as human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS); 5.Patients with severe acute liver failure (defined as prothrombin activity [PTA] 65 mmHg despite vasopressor support equivalent to >=1 µg·kg?¹·min?¹ of norepinephrine (dose conversion criteria refer to Appendix 1); 12.The investigator deems that participation in the trial poses significant risks to the patient's health or safety, may compromise efficacy evaluation, or presents other conditions unsuitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in inflammatory cytokine levels (IL-6, CRP, PCT); | — |
Secondary
| Measure | Time frame |
|---|---|
| Other inflammation-related cytokines: IL-10, IL-1, TNF-a, IL-4, IL-8, IL-2, IL-35, HMGB-1, IFN-?; | — |
Countries
China
Contacts
Public ContactQindong Shi
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed